- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06335576
Establishment of Serum Proteomics Subtypes of Gastric Cancer and Its Clinical Application
Establishment of Serum Proteomics Subtypes of Gastric Cancer and Its Clinical
This study is a prospective, single-center, observational study aimed at detecting the status of serum protein profiles at key time points in gastric cancer patients receiving neoadjuvant therapy for advanced disease, and constructing a serum protein model for evaluating the efficacy of neoadjuvant therapy for gastric cancer. Subjects will receive neoadjuvant therapy (treatment regimen determined by the primary physician, limited to systemic therapy, with options including immune checkpoint inhibitor-based regimens and non-immune checkpoint inhibitor-based regimens). After four cycles of treatment, the efficacy will be assessed. Patients eligible for R0 resection will undergo D2 radical surgery regardless of tumor regression, while those ineligible for R0 resection will enter the palliative treatment phase (Note: Subjects are all patients who require neoadjuvant therapy even if they do not participate in this clinical study). Patients will receive regular follow-up evaluations for metastasis/recurrence and survival until tumor recurrence/progression or the last known date of patient survival (Note: Regular follow-up in this study follows the frequency of routine clinical follow-ups). The primary endpoint is progression-free survival (PFS), and the secondary endpoint is pathological response rate (based on Becker tumor regression grading, with residual tumor less than 50% considered effective preoperative treatment).
Peripheral venous blood samples will be collected before the start of neoadjuvant therapy (blood sampling point 1 - baseline) and before surgery after neoadjuvant therapy (blood sampling point 2 - post-treatment). Approximately 3 ml of blood will be collected each time, and about 1.5 ml of serum will be obtained after processing. Serum protein profiling will be conducted to assess the expression of protein profiles at these treatment time points.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Zhaoqing Tang, PhD
- Phone Number: +86 13817125778
- Email: tang.zhaoqing@zs-hospital.sh.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female, aged 18 and ≤ 75 years old.
- KPS score ≥ 80 points within 7 days prior to enrollment.
- Histologically confirmed gastric adenocarcinoma at initial diagnosis.
- Tumor located in the proximal stomach, including the gastroesophageal junction (defined as within 5cm proximal and distal to the cardia), gastric fundus, and upper body of the stomach.
- Clinical staging based on endoscopic ultrasound or enhanced CT/MRI examination, staged as cT3~4aN+M0 (according to the 8th edition of AJCC TNM).
- Presence of at least one evaluable lesion according to RECIST 1.1 criteria on abdominal CT/MRI examination.
- Surgeon participating in this study determines that curative surgical resection is feasible.
- Major organ function is able to tolerate neoadjuvant therapy.
- No accompanying diseases that significantly reduce survival expectancy to < 5 years.
- Willingness and ability to comply with the study protocol during the study period.
- Provide written informed consent prior to entering the study, and the patient understands that they can withdraw from the study at any time without any loss.
Exclusion Criteria:
- Patients with signs of distant metastasis or local unresectable factors.
- Patients with imaging or endoscopic ultrasound suggesting T1 or T2 disease.
- Patients who have received cytotoxic chemotherapy, radiotherapy, immunotherapy, or curative surgery for gastric cancer, excluding corticosteroids.
- Patients who have experienced gastrointestinal bleeding within the two weeks prior to enrollment or are judged by the investigator to be at high risk of bleeding.
- Patients with upper gastrointestinal obstruction, physiological dysfunction, or malabsorption syndrome that may affect oral drug absorption.
- Patients who have received live vaccines within 4 weeks prior to enrollment. (Note: Seasonal influenza vaccines, which are usually inactivated vaccines, are allowed. Vaccines administered intranasally are live vaccines and are not allowed.)
- Patients who have received immunotherapy (such as interleukins, interferons, thymosin, etc.) or any investigational treatment within 28 days prior to enrollment or within 5 half-lives (whichever is shorter, but at least 14 days).
- Patients who have undergone major surgery within 28 days prior to enrollment, unless the surgery was minimally invasive (e.g., peripherally inserted central catheter [PICC] via peripheral venous puncture).
- Uncontrolled systemic diseases.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Gastric cancer patients receiving adjuvant chemotherapy
|
This study is a single-arm and observational study with no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-index
Time Frame: started 03-31-2024
|
Effectiveness of the constructed serum protein model in predicting the efficacy of neoadjuvant chemotherapy for locally advanced gastric cancer (C-index)
|
started 03-31-2024
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of model
Time Frame: started 03-31-2024
|
Sensitivity and specificity of the constructed serum protein model in predicting the efficacy of neoadjuvant chemotherapy for locally advanced gastric cancer.
|
started 03-31-2024
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZSGCproteomics
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on This study is a single-arm and observational study with no intervention.
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)CompletedThe Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural ConnectivityDrug Use | Neurodevelopmental Abnormality | Cannabis Use Disorder | PREG1 | Fetal Exposure During PregnancyUnited States
-
University of HaifaRambam Health Care CampusCompletedParkinson DiseaseIsrael
-
The University of Texas Health Science Center,...CompletedWound InfectionUnited States
-
Walter Reed National Military Medical CenterJohns Hopkins UniversityRecruitingTraumatic Brain Injury | Vascular Dementia | Cognitive DeclineUnited States
-
Ohio State UniversityAbbVieActive, not recruiting
-
Zenalux Biomedical, Inc.National Cancer Institute (NCI); Duke UniversityUnknownSquamous Cell CarcinomaUnited States
-
Chisquares IncorporatedNot yet recruitingCOVID-19 | Burnout, Professional | Patient Engagement | Artificial Intelligence | Substance Use Disorders | Mental Health Issue | Climate Change | Preventable Disease, Vaccine | Emerging Infectious Disease | Online Education
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingAcute-On-Chronic Liver FailureIndia
-
Duke UniversityCompletedSuspicious Skin Lesion(s) Requiring a BiopsyUnited States